Unravelling immune thrombocytopenia: from diagnosis to treatment options

Immune thrombocytopenia (ITP) is a poorly understood life-threatening bleeding disorder of accelerated platelet destruction and in 2023, remains a diagnosis of exclusion.First-line treatment usually involves prolonged courses of high doses corticosteroids which cause considerable side effects if unable to be promptly tapered.There are no tools to predict response to therapy or to guide the selection of appropriate alternative therapies for patients who fail to respond.